Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul 6;222(3):509-510.
doi: 10.1093/infdis/jiaa312.

Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019

Miroslav Malkovsky  1
Affiliations
Comment

Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019

Miroslav Malkovsky. J Infect Dis. .
No abstract available

PubMed Disclaimer

Comment in

  • Response to Malkovsky.
    Zeng QL, Ji F, Zhang JY. Zeng QL, et al. J Infect Dis. 2020 Jul 6;222(3):510-511. doi: 10.1093/infdis/jiaa313. J Infect Dis. 2020. PMID: 32473012 Free PMC article. No abstract available.

Comment on

References

    1. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis doi:10.1093/infdis/jiaa228. - PMC - PubMed
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323:1582–9. - PMC - PubMed
    1. Knaup H, Stahl K, Schmidt BMW, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 2018; 22:285. - PMC - PubMed
    1. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care 2020; 24:128. - PMC - PubMed
    1. Blanco-Melo D, Nilsson-Payant BE, Liu W C, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181:1–10. - PMC - PubMed

Substances